In summary, the results of this meta-analysis indicate that intrauterine administration of G-CSF and its use during the ovulatory phase can significantly reduce the risk of miscarriage for patients with recurrent miscarriage and increase the rate of live births, making it worthy of promotion and application. Here, CSF3 is linked to Miscarriage.